Your browser is no longer supported. Please, upgrade your browser.
Settings
AKRO [NASD]
Akero Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.49 Insider Own1.90% Shs Outstand34.74M Perf Week-4.16%
Market Cap766.69M Forward P/E- EPS next Y-3.49 Insider Trans-15.11% Shs Float24.45M Perf Month-13.58%
Income-82.40M PEG- EPS next Q-0.75 Inst Own81.30% Short Float14.44% Perf Quarter-30.39%
Sales- P/S- EPS this Y13.30% Inst Trans-16.90% Short Ratio15.57 Perf Half Y-27.12%
Book/sh7.08 P/B3.03 EPS next Y-11.50% ROA-34.90% Target Price- Perf Year-40.64%
Cash/sh6.99 P/C3.07 EPS next 5Y- ROE-36.80% 52W Range20.81 - 37.94 Perf YTD-16.90%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.49% Beta-
Dividend %- Quick Ratio25.20 Sales past 5Y- Gross Margin- 52W Low3.03% ATR1.16
Employees21 Current Ratio25.20 Sales Q/Q- Oper. Margin- RSI (14)33.51 Volatility5.17% 4.86%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.10% Profit Margin- Rel Volume1.06 Prev Close21.64
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume226.77K Price21.44
Recom1.60 SMA20-7.92% SMA50-17.48% SMA200-23.84% Volume239,878 Change-0.92%
Feb-26-21Initiated Guggenheim Buy $54
Sep-10-20Initiated Morgan Stanley Overweight $70
Jul-20-20Reiterated H.C. Wainwright Buy $45 → $62
Jul-07-20Initiated Chardan Capital Markets Buy $79
Jul-01-20Reiterated H.C. Wainwright Buy $33 → $45
Mar-02-20Initiated H.C. Wainwright Buy $33
Feb-10-20Initiated Canaccord Genuity Buy $36
Jul-15-19Initiated ROTH Capital Buy $34
Jul-15-19Initiated JP Morgan Overweight $28
Jul-15-19Initiated Jefferies Buy $28
Jul-15-19Initiated Evercore ISI Outperform $35
Jul-14-21 08:00AM  
Jul-08-21 01:24PM  
11:10AM  
Jun-25-21 11:30AM  
Jun-21-21 11:33AM  
08:00AM  
Jun-09-21 10:03AM  
09:06AM  
Jun-01-21 08:00AM  
May-28-21 04:05PM  
10:09AM  
May-13-21 07:00AM  
Apr-26-21 08:00AM  
Mar-23-21 08:00AM  
Mar-22-21 04:01PM  
06:30AM  
Mar-16-21 08:00AM  
Mar-11-21 11:40PM  
Feb-24-21 08:30AM  
Feb-23-21 04:05PM  
Jan-04-21 04:05PM  
Dec-12-20 10:07PM  
Nov-24-20 04:05PM  
Nov-13-20 08:00AM  
Nov-12-20 04:05PM  
Oct-21-20 04:05PM  
Oct-19-20 10:13AM  
Oct-16-20 07:30AM  
Oct-02-20 07:30AM  
Sep-30-20 08:00AM  
Sep-28-20 04:05PM  
Sep-24-20 07:30AM  
Sep-16-20 04:25PM  
Sep-13-20 08:48AM  
Sep-09-20 04:05PM  
Aug-12-20 04:05PM  
Jul-23-20 11:02AM  
Jul-21-20 11:00AM  
Jul-10-20 04:05PM  
Jul-07-20 08:15PM  
Jul-06-20 07:00AM  
Jul-02-20 08:21AM  
Jul-01-20 09:03AM  
08:12AM  
Jun-30-20 04:05PM  
Jun-29-20 04:05PM  
Jun-27-20 09:28PM  
Jun-17-20 08:00AM  
Jun-10-20 12:00PM  
11:30AM  
10:30AM  
08:00AM  
Jun-04-20 07:08AM  
May-27-20 09:24AM  
May-26-20 04:05PM  
May-22-20 11:30AM  
May-13-20 04:05PM  
May-08-20 12:00PM  
Apr-06-20 12:00PM  
08:58AM  
Mar-31-20 08:26AM  
06:00AM  
Mar-30-20 04:05PM  
Mar-16-20 11:19AM  
07:31AM  
Feb-14-20 11:55AM  
Jan-27-20 06:05AM  
Jan-13-20 08:00AM  
Jan-08-20 04:05PM  
Dec-19-19 05:51PM  
Dec-16-19 04:05PM  
Dec-14-19 07:22PM  
Nov-13-19 04:01PM  
Nov-12-19 07:00AM  
Nov-04-19 08:00AM  
Oct-31-19 02:07PM  
Sep-19-19 06:54AM  
Sep-04-19 07:00AM  
Aug-12-19 07:00AM  
Jul-09-19 10:07AM  
Jul-03-19 07:31AM  
Jul-02-19 04:05PM  
Jun-24-19 04:05PM  
Jun-20-19 11:44AM  
Jun-19-19 09:20PM  
Jun-18-19 12:10PM  
Jun-17-19 10:07AM  
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Young JonathanChief Operating OfficerJul 15Option Exercise0.619,0005,535173,010Jul 19 04:43 PM
Yale CatrionaChief Development OfficerJul 15Sale20.9010,000209,044155,921Jul 19 04:43 PM
White William RichardChief Financial OfficerJul 06Option Exercise7.016,50045,5589,777Jul 08 07:19 PM
White William RichardChief Financial OfficerJul 06Sale24.526,500159,3803,277Jul 08 07:19 PM
Cheng AndrewPresident & CEOJul 02Sale24.7817,500433,650342,489Jul 06 05:52 PM
Young JonathanChief Operating OfficerJun 01Sale26.243,05580,151164,010Jun 02 04:06 PM
Bitterman KevinDirectorJun 01Sale26.2817,489459,6110Jun 03 08:07 PM
White William RichardChief Financial OfficerMay 03Option Exercise7.014,20029,4386,470May 04 04:06 PM
White William RichardChief Financial OfficerMay 03Sale30.564,200128,3522,270May 04 04:06 PM
Young JonathanChief Operating OfficerMay 03Sale30.563,05593,361167,065May 04 04:06 PM
White William RichardChief Financial OfficerApr 01Option Exercise7.0150,000350,50052,270Apr 05 05:14 PM
White William RichardChief Financial OfficerApr 01Sale28.6450,0001,432,1662,270Apr 05 05:14 PM
Young JonathanChief Operating OfficerApr 01Sale28.753,05587,828170,120Apr 05 05:15 PM
Young JonathanChief Operating OfficerMar 01Sale30.483,05593,112173,175Mar 02 05:56 PM
Young JonathanChief Operating OfficerFeb 01Sale29.243,05589,321176,230Feb 02 04:08 PM
Young JonathanChief Operating OfficerJan 08Sale28.1210,000281,200179,285Jan 11 07:54 PM
Cheng AndrewPresident & CEOJan 07Option Exercise0.6120,00012,300362,989Jan 11 07:57 PM
Young JonathanChief Operating OfficerJan 07Option Exercise0.617,5004,612189,285Jan 11 07:54 PM
Young JonathanChief Operating OfficerJan 04Sale25.293,06077,399181,785Jan 06 06:48 PM
Cheng AndrewPresident & CEODec 28Option Exercise0.627,4804,638342,989Dec 29 04:53 PM
Cheng AndrewPresident & CEODec 21Option Exercise0.6210,5006,510335,509Dec 23 04:19 PM
Bitterman KevinDirectorOct 09Sale28.9313,000376,09011,780Oct 14 04:54 PM